DelveInsight’s, “Chronic Pulmonary Infections Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Chronic Pulmonary Infections pipeline landscape. It covers the Chronic Pulmonary Infections pipeline drug profiles, including Chronic Pulmonary Infections clinical trials and nonclinical stage products. It also covers the Chronic Pulmonary Infections therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Recent Developmental Activities in the Chronic Pulmonary Infections Treatment Landscape
- In May, 2023, The Bausch + Lomb Miebo drops for dry eye condition received FDA approval on Thursday. According to Bausch + Lomb CEO Brent Saunders, the medication fills a critical medical need for patients and is the first FDA-approved treatment to target tear evaporation directly.
- On 8 September 2020, Synairgen announced positive data from the interim analysis of its Phase II clinical trial of inhaled SNG001 in COPD patients with a confirmed respiratory viral infection.
Request a sample and discover the recent breakthroughs happening in the Chronic Pulmonary Infections Pipeline landscape @ Chronic Pulmonary Infections Pipeline Outlook
Chronic Pulmonary Infections Overview
Lung infections are very common and are caused by viruses, bacteria and fungal organisms. Chronic lung (or pulmonary) infections affect the lower respiratory tract and can be very debilitating. The most common causes are from chronic obstructive pulmonary disease (COPD), cystic fibrosis, and bronchiectasis, all of which involve inability to clear secretions.
Key Takeaways from the Chronic Pulmonary Infections Pipeline Report
- DelveInsight’s Chronic Pulmonary Infections Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Chronic Pulmonary Infections treatment.
- The leading Chronic Pulmonary Infections Companies include Armata Pharmaceuticals, Synairgen, Ionis Pharmaceuticals, AstraZeneca, Zambon SpA, Chiesi Farmaceutici, Gilead Sciences, Aradigm Corporation, Grifols Therapeutics LLC, Savara Inc. Amgen, Pfizer, GSKand others
- Promising Chronic Pulmonary Infections Pipeline Therapies include AZLI, Tobramycin inhalation solution, Colistimethate sodium, Saline Solution, Ciprofloxacin dispersion for inhalation, Tiotropium, Focetria®, Enbrel, fluticasone propionate/salmeterol combination DISKUS, and others.
- The Chronic Pulmonary Infections companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pulmonary Infections R&D. The Chronic Pulmonary Infections therapies under development are focused on novel approaches to treat/improve Chronic Pulmonary Infections.
For further information, refer to the detailed Chronic Pulmonary Infections Drugs Launch, Chronic Pulmonary Infections Developmental Activities, and Chronic Pulmonary Infections News, click here for Chronic Pulmonary Infections Ongoing Clinical Trial Analysis
Chronic Pulmonary Infections Emerging Drugs Profile
- AP-PA02: Armata Pharmaceuticals
AP-PA02 is a therapeutic phage cocktail that targets the pathogen P. aeruginosa, to treat serious respiratory infections, with an initial emphasis on cystic fibrosis (CF) patients. AP-PA02 is comprised of a cocktail of complementary P. aeruginosa phages that offer improved host range, increased potency, and aid in preventing the development of resistance. AP-PA02 demonstrates broad coverage against relevant clinical isolates. Armata Pharmaceuticals plans to initiate the multiple ascending dose cohort of the phase Ib/IIa SWARM-P.a. trial for Pseudomonal infections, in 2022
- Interferon Beta-1A inhalation (SNG-001): Synairgen
SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function and, in more difficult to treat patients, improves asthma control during cold infections. On 8 September 2020, Synairgen announced positive data from the interim analysis of its Phase II clinical trial of inhaled SNG001 in COPD patients with a confirmed respiratory viral infection.
Chronic Pulmonary Infections Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Chronic Pulmonary Infections. The companies which have their Chronic Pulmonary Infections drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Amrata Pharmaceuticals and others.
Find out more about the Chronic Pulmonary Infections Pipeline Segmentation, Therapeutics Assessment, and Chronic Pulmonary Infections Emerging Drugs @ Chronic Pulmonary Infections Treatment Landscape
Scope of the Chronic Pulmonary Infections Pipeline Report
- Coverage- Global
- Chronic Pulmonary Infections Companies- Armata Pharmaceuticals, Synairgen, Ionis Pharmaceuticals, AstraZeneca, Zambon SpA, Chiesi Farmaceutici, Gilead Sciences, Aradigm Corporation, Grifols Therapeutics LLC, Savara Inc. Amgen, Pfizer, GSKand others
- Chronic Pulmonary Infections Pipeline Therapies- AZLI, Tobramycin inhalation solution, Colistimethate sodium, Saline Solution, Ciprofloxacin dispersion for inhalation, Tiotropium, Focetria®, Enbrel, fluticasone propionate/salmeterol combination DISKUS, and others
- Chronic Pulmonary Infections Pipeline Segmentation: Product Type, Molecule Type Route of Administration
Dive deep into rich insights for drugs for Chronic Pulmonary Infections Pipeline Companies and Therapies, click here @ Chronic Pulmonary Infections Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Chronic Pulmonary Infections: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chronic Pulmonary Infections – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Chronic Pulmonary Infections Collaboration Deals
- Late Stage Products (Phase III)
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- AP-PA02: Armata Pharmaceuticals
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Drug profiles in the detailed report…..
- Inactive Products
- Chronic Pulmonary Infections Key Companies
- Chronic Pulmonary Infections Key Products
- Chronic Pulmonary Infections- Unmet Needs
- Chronic Pulmonary Infections- Market Drivers and Barriers
- Chronic Pulmonary Infections- Future Perspectives and Conclusion
- Chronic Pulmonary Infections Analyst Views
- Chronic Pulmonary Infections Key Companies
- Appendix
Got Queries? Find out the related information on Chronic Pulmonary Infections Mergers and acquisitions, Chronic Pulmonary Infections Licensing Activities @ Chronic Pulmonary Infections Recent Trends, and Future Perspectives
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/